Back to Journals » OncoTargets and Therapy » Volume 12

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Authors Baldini C, Champiat S, Vuagnat P, Massard C

Received 2 December 2018

Accepted for publication 1 February 2019

Published 3 April 2019 Volume 2019:12 Pages 2505—2512

DOI https://doi.org/10.2147/OTT.S141040

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 4

Editor who approved publication: Dr Sanjeev Srivastava


Capucine Baldini, Stéphane Champiat, Perrine Vuagnat, Christophe Massard

Drug Development Department, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France

Abstract: Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression

Keywords: immunotherapy, PD-L1 inhibitor, durvalumab, urothelial carcinoma, bladder cancer


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]